A Meta-Analysis of Exercise Intervention for Depression Symptoms

Summary

Exercise significantly increased depression remission rates (OR = 2.40) and reduced symptom severity (SMD = –0.96) in 40 RCTs (2,667 participants). These findings support exercise as a complementary approach, though heterogeneity and bias limit certainty.

Abstract

This meta‑analysis estimated the effect of exercise on depression symptoms. Unlike network meta‑analyses that compare exercise modalities, this pairwise meta‑analysis specifically quantifies the effect of structured exercise versus no exercise, using rigorous control-group definitions and updated methods. A literature search up to November 2025 identified 10,123 records. Forty randomized controlled trials met the inclusion criteria. Pooled effect sizes were calculated using random‑effects models; odds ratios (OR) for remission and standardized mean differences (SMD) for depression scores. Heterogeneity was assessed with I². Exercise significantly increased remission rates (OR = 2.40; 95% CI, 1.97–2.93; p < 0.001; I² = 49%) and reduced depression scores (SMD = –0.96; 95% CI, –1.27 to –0.65; p < 0.001; I² = 87%) compared to control groups. The number needed to treat for one additional remission was 2.1. The pooled SMD corresponded to clinically meaningful reductions. Subgroup analyses showed larger effects for supervised exercise and passive controls (e.g., waitlist) versus active comparators (e.g., pharmacotherapy). However, findings have major limitations; only 12/40 studies (30%) had low-risk of bias (RoB 2); most had short follow‑up (≤16 weeks); control conditions varied widely (waitlist to pharmacotherapy); and very high heterogeneity for depression scores (I² = 87%) persisted despite using SMD. The 95% prediction interval for SMD crossed zero, indicating exercise may not benefit all future populations. Grading of Recommendations Assessment, Development and Evaluation (GRADE) was moderate for remission but low for depression scores. Despite these limitations, exercise was associated with significantly higher remission and lower depression scores. These results support exercise as a complementary approach for depression, particularly for achieving remission. However, high‑quality, large‑scale RCTs with standardized outcomes and longer follow‑up are needed before clinical recommendations can be made.

Introduction

Depression is a common and incapacitating mental illness linked to higher mortality, medical comorbidity, and lower quality of life¹. More than 300 million people, or around 4.4% of the global population, suffer from depression². Psychotherapy and antidepressant medication (or a mix of both) are currently advised therapies³. However, psychotherapy is usually expensive and only produces remission rates of 50%⁴. Antidepressant medication frequently causes withdrawal symptoms, relapses, and side effects⁵. Notably, around two-thirds of adults who suffer from depression do not obtain proper care⁶. Depression that goes untreated frequently worsens and can result in comorbidities, which raises the expenses to society even more⁷. Both the national institute for health and care excellence (NICE) and the WHO advocate exercise as a supplemental treatment for depression^8,9.

Results from several meta-analyses examining the antidepressant impact of exercise on individuals with depression provided evidence in support of these suggestions^10,11,12. Nevertheless, some of these meta-analyses⁸ indicated significant effects of exercise, whereas others identified moderate to weak effects^11,12. Methodological and conceptual disagreements over inclusion criteria and analysis techniques are the cause of these conflicting findings. For instance, some research excluded studies that assessed the existence of depression using established screening tools and instead concentrated on those with a major depressive disorder diagnosis⁸. For research published between 2003 and 2019, others examined the impact of exercise either by itself or in conjunction with pharmaceutical treatments as a treatment for depression^11,12. Additionally, trials where patients in the control groups also received exercise interventions¹³ were included in certain reviews. Given that even mild exercise might have antidepressant benefits, this raises the possibility of bias¹⁴.

Crucially, a number of evaluations have expressed concern that, when limited to "low-risk of bias" randomized controlled trials (RCTs), exercise had no discernible impact^8,13. As a result, current meta-analyses have not produced strong enough data to support the use of exercise as an evidence-based, successful depression therapy choice by doctors worldwide. These methodological flaws were addressed by one meta-analysis¹¹, which only included studies that compared exercise to non-active controls and concentrated on studies that included samples with major depressive disorder diagnosed using diagnostic tools and samples with depression using cut-offs on validated screening instruments. Trials comparing various exercise regimens were not included by the authors. However, a significant number of papers have been published recently, necessitating an updated meta-analysis of exercise's antidepressant effects that addresses the limitations of earlier reviews.

This demonstrates the necessity of quick, accessible alternative treatment options. Recent systematic reviews have confirmed that structured physical activity and exercise programs consistently improve depressive symptoms and related mental health outcomes, supporting exercise as a potentially scalable adjunctive or complementary approach^15,16. The manuscript includes multiple forms of exercise, including aerobic exercise, resistance training, mixed exercise, yoga, tai chi, dance, and other mind-body approaches. However, the discussion still tends to describe "exercise" as a single intervention category¹⁵. Despite the growing evidence base for exercise as a treatment for depression, several unresolved issues justify an updated meta-analysis. First, prior meta-analyses have produced conflicting conclusions. These discrepancies arise from methodological differences, including the inclusion of studies with active control groups (e.g., stretching, relaxation, or psychotherapy), which may attenuate effect sizes; the inclusion of studies in which control groups also received exercise interventions; and the use of different risk-of-bias assessment tools. Second, the most recent comprehensive meta-analyses in this area were published in 2016–2019^10,11,12. Since 2019, at least 23 new randomized controlled trials have been published (as identified in this search), substantially increasing the available evidence base. An updated synthesis is therefore necessary to incorporate this new data and determine whether the cumulative evidence supports or refutes earlier conclusions.

Third, prior meta-analyses have not consistently addressed key methodological issues that affect clinical interpretation. These include the use of appropriate effect metrics for continuous outcomes measured on different depression scales (standardized mean difference rather than mean difference), the handling of heterogeneous control conditions (passive vs. active comparators), the inclusion of studies where depression was a secondary outcome in non-psychiatric populations, the assessment of publication bias in the context of high heterogeneity, and the calculation of prediction intervals to communicate the range of expected effects in future studies. Fourth, no prior meta-analysis has systematically examined moderators of exercise efficacy across the full range of potential effect modifiers, including exercise mode (aerobic, resistance, mixed, yoga), intensity (light, moderate, vigorous), duration, supervision, format (group vs. individual), control type, depression diagnosis (MDD vs. screening-based), age group, and risk of bias. Understanding these moderators is essential for prescribing exercise.

This meta-analysis addresses these gaps through the following innovations. First, an updated evidence base includes studies published through November 2025, capturing 23 new trials not included in prior meta-analyses. Next, a methodologically rigorous inclusion criterion was used, where only studies that compared exercise to non-exercising control groups (excluding trials in which control groups received stretching, relaxation, or active psychological interventions) were included to isolate the specific effect of exercise. Third was the appropriate effect metric, with standardized mean difference (SMD) rather than mean difference, for continuous depression outcomes, acknowledging that studies used different depression scales. Fourth was comprehensive moderator analyses, in which prespecified subgroup analyses of exercise characteristics, population characteristics, and study design features were conducted to identify conditions under which exercise is most effective. Next was the current risk-of-bias assessment in which the updated RoB 2 tool (2019 version) was used rather than the older RoB 1 tool employed in prior meta-analyses. Another one was clinical interpretability in which the number needed to treat (NNT) was calculated, SMD was converted to clinically familiar metrics (BDI and HAM-D points), and prediction intervals were reported to communicate the expected range of effects in future applications. The final one was the certainty of evidence, in which the GRADE (Grading of Recommendations Assessment, Development and Evaluation) was applied to rate the certainty of evidence for each outcome, a rating that has not been consistently reported in prior exercise-depression meta-analyses.

Although recent network meta‑analyses (NMAs) and umbrella reviews have synthesized evidence on exercise for depression, none directly answer the foundational pairwise question, "Does any structured exercise reduce depressive symptoms compared to no exercise?" NMAs pool across heterogeneous control conditions (waitlist, pharmacotherapy, psychotherapy) to compare modalities, which obscures the specific effect of exercise versus true inactivity. Umbrella reviews aggregate prior meta‑analyses that used different inclusion criteria and risk‑of‑bias tools, leaving methodological heterogeneity unresolved. This pairwise meta‑analysis fills this specific gap by providing a single, up‑to‑date, internally consistent estimate of exercise versus non‑exercising control using prespecified eligibility, RoB 2, GRADE, prediction intervals, and NNT – including 23 new trials not yet synthesized in this framework. This foundational estimate complements NMAs by answering whether exercise works before asking which exercise works best.

Exercise is a behavioral intervention, not a medication. Throughout this manuscript, exercise is compared to pharmacotherapy and psychotherapy using metrics such as number needed to treat (NNT) and remission rates. This “exercise as medication” framing is useful for clinical communication and guideline development because it allows direct comparison of effect sizes across treatment modalities using common metrics. However, important distinctions must be acknowledged. Exercise is a complex behavioral intervention that requires active patient participation, motivation, and often supervision or environmental support. Unlike a pill, exercise has no direct biological target, no standardized dose–response curve across individuals, and adherence is heavily influenced by psychosocial factors such as depression-related anhedonia and fatigue. Moreover, exercise does not carry the same side-effect profile (e.g., no withdrawal syndromes or metabolic disturbances) but does pose injury risk and logistical barriers. Therefore, while comparative effect estimates are presented, the intention is not to suggest that exercise is interchangeable with medication; rather, exercise should be viewed as a complementary, patient‑centered option with distinct implementation requirements.

This meta-analysis aimed to compare exercise with non-exercising control groups in order to update the current evidence on the effects of exercise in lowering depressive symptoms in individuals with clinically elevated levels of depression, including major depressive disorder and dysthymia. The existence of publication bias and possible moderators of exercise's antidepressant effects were also examined. Hence, the meta-analysis evaluated exercise intervention for depression symptoms.

Protocol

Eligibility criteria

Studies were included if they met all of the following criteria, organized according to the PICOS framework (Population, Intervention, Comparator, Outcomes, Study design)¹⁷. All platforms and materials used in this study are listed in the Table of Materials. All database searches were performed in November 2025. No additional proprietary software (e.g., SAS, SPSS, R) was used beyond RevMan 5.3 and EndNote 20. The GRADE assessment was performed manually using the GRADEpro GDT online tool; the version is recorded as of the access date.

Population (P)

Participants had clinically significant depressive symptoms, defined as either a formal diagnosis of major depressive disorder (MDD) or dysthymia according to DSM criteria (any version) or ICD criteria, confirmed by structured clinical interview (e.g., SCID, MINI, CIDI); or a score above the validated cutoff on a standardized depression screening instrument (e.g., Beck Depression Inventory ≥ 14, Hamilton Depression Rating Scale ≥ 14, CES-D ≥ 16, PHQ-9 ≥ 10, Geriatric Depression Scale ≥ 11). Participants could be of any age (children, adolescents, adults, older adults)¹⁸. Studies that enrolled participants with comorbid medical or psychiatric conditions (e.g., cardiovascular disease, diabetes, anxiety disorders, substance use disorders) were included only if the primary analysis reported results separately for the depression subgroup or if ≥80% of participants met depression criteria. Studies where depression was a secondary outcome in a non-depressed population (e.g., heart failure patients without depression screening) were excluded. There was no restriction on baseline depression severity (mild, moderate, severe), but severity was extracted for subgroup analyses.

Intervention (I)

The intervention consisted of structured, planned physical exercise, defined as any form of aerobic, resistance, mixed (aerobic + resistance), or alternative exercise (yoga, tai chi, dance) delivered for at least 2 weeks. Exercise interventions could be supervised (by a trainer, therapist, or instructor) or unsupervised (home-based, self-directed). Studies where exercise was combined with another active intervention (e.g., exercise + pharmacotherapy, exercise + mindfulness) were included only if the effect of exercise could be isolated (e.g., exercise + pharmacotherapy vs. pharmacotherapy alone). Studies where the intervention consisted only of physical activity advice (without structured exercise prescription) or lifestyle counseling were excluded.

Comparator (C)

The control group received no structured exercise intervention. Acceptable control conditions were categorized as passive controls (no active therapeutic intervention) e.g. waitlist (delayed treatment), usual care (standard medical management without structured exercise), or no intervention; and active controls (non‑exercise therapeutic interventions) e.g. attention control (e.g., non‑exercise health education, relaxation sessions, or light stretching not meeting exercise intensity criteria), pharmacotherapy (antidepressant medication alone), or psychotherapy (psychological therapy without exercise). Studies in which the control group received any form of structured exercise (including minimal exercise or stretching that met the exercise intensity criteria) were excluded. Note on discrepancy, although the innovation section stated that studies with active psychological interventions or stretching/relaxation controls were excluded, subsequently, the eligibility criteria to include active comparators (pharmacotherapy, psychotherapy, attention control) to reflect the real‑world clinical question of how exercise compares to other established treatments were broadened. This discrepancy is addressed in the discussion. All analyses stratify by control type (passive vs. active) to examine the influence of control type on effect sizes.

Outcomes (O)

The study reported at least one depression-specific outcome measure: depression remission (dichotomous, defined by study authors as no longer meeting diagnostic criteria or scoring below the cutoff on a validated scale); OR (b) change in continuous depression severity score measured on a validated scale (e.g., HAM-D, BDI, CES-D, PHQ-9, GDS, MADRS). Studies reporting only non-specific mood measures (e.g., “well-being,” “emotional state” without a validated depression scale) were excluded.

Study design (S)

Only randomized controlled trials (RCTs) were included. Prospective cohort studies, case-control studies, retrospective studies, case series, and case reports were excluded because they are at high risk of confounding and selection bias when estimating treatment effects. Studies could be parallel-group or crossover design (only the first phase extracted for crossover trials). Studies were required to have at least 10 participants per arm at baseline to minimize small-study effects. No language restrictions were applied, but non-English studies were included only if a full translation was available.

Exclusion criteria

Studies where depression was not the primary outcome or where the population was not selected for depression (e.g., general medical populations with depression as a secondary measure) were excluded. Studies in which the exercise intervention was delivered as part of a multi-component lifestyle intervention, without an isolated exercise effect, were excluded. Studies where the control group received any form of structured exercise were excluded. Studies with insufficient data to calculate effect sizes (means, standard deviations, or change scores not reported and not obtainable from authors) were excluded. Duplicate publications of the same study cohort (only the most complete or most recent report was included) were excluded. Conference abstracts, dissertations, and unpublished manuscripts without full-text availability were excluded.

Information sources

The full study is shown in Figure 1 as a PRISMA Flowchart. Literature was included in the study if the following inclusion criteria were met: the study was a randomized controlled trial (RCT); the patients selected for investigation had depression; and the control condition was non-exercise. Acceptable control groups included usual care (standard medical management without structured exercise), waitlist (delayed treatment), no intervention, attention control (e.g., non-exercise health education, relaxation sessions, or light stretching not meeting exercise prescription criteria), or pharmacological treatment (antidepressants alone). Studies where the control group received any structured aerobic, resistance, or mixed exercise training were excluded. Studies where control groups received psychotherapy or cognitive-behavioral therapy without an exercise component were included only if clearly defined as non-exercising.

The study compared exercise interventions to control conditions. Control groups were defined as non-exercising comparators, including usual care, waitlist, no treatment, attention control (e.g., health education, relaxation, or stretching activities that did not meet exercise intensity criteria), or pharmacological treatment alone. Studies were excluded if the control group received any structured exercise intervention or if exercise was compared only to another exercise regimen, without a non-exercising control arm. Studies that did not evaluate the effects of exercise intervention for depression symptoms, studies on depression in patients without exercise or control, and studies with no comparison group were excluded.

Handling of multi-arm studies
For studies with more than two relevant arms (e.g., multiple exercise interventions or multiple comparator groups), the following strategies were applied to avoid double-counting and unit-of-analysis errors as multiple exercise arms vs. single control arm When a study compared two or more different exercise interventions (e.g., aerobic vs. resistance training) to a single control group, the exercise arms were combined into a single pooled exercise group using formulas recommended by the Cochrane Handbook (Chapter 23). This approach avoids double-counting the control group participants while preserving statistical independence; exercise vs. multiple non-exercise comparators. When a study compared exercise to two or more distinct control conditions (e.g., usual care and pharmacotherapy), only the control condition that best aligned with the definition of 'non-exercising control' was selected (priority order: waitlist ≥ usual care ≥ attention control > pharmacotherapy > psychotherapy).

If multiple non-exercising controls were present, the most conservative (least active) comparator to avoid overestimating the effect of exercise was selected; exercise vs. exercise only (no non-exercising control). Studies that compared only different types of exercise (e.g., high-intensity vs. low-intensity) without a non-exercising control arm were excluded from the primary analysis, as they did not meet the comparison criterion of 'exercise vs. control'. Combined interventions for studies, where the intervention arm included exercise plus another active component (e.g., exercise + pharmacotherapy, exercise + mindfulness), the arm was included only if the effect of exercise could be isolated. If the combined arm was compared to the same non-exercise component alone (e.g., exercise + pharmacotherapy vs. pharmacotherapy alone), the difference was interpreted as reflecting the effect of exercise. If no such isolation was possible, the study was excluded. To assess the robustness of the pooling strategy for multi-arm trials, a sensitivity analysis excluding all multi-arm studies was conducted, and the results were compared with those of the primary analysis. Any substantial differences are reported.

Selection of control arm when multiple non‑exercise comparators are present was done in the following manner: if a study compared exercise to two or more distinct control conditions (e.g., usual care and pharmacotherapy), a hierarchical selection rule to avoid arbitrary choices was applied as passive controls (waitlist ≥ usual care ≥ no intervention) prioritized over active controls to better isolate the specific effect of exercise. If only active controls were available, the most conservative comparator (pharmacotherapy ≥ psychotherapy ≥ attention control) to avoid overestimating the exercise effect was selected, and sensitivity analyses were conducted, including all available control arms (by splitting the exercise group across comparators) to test whether the selection rule influenced the pooled estimate. Results of these sensitivity analyses are reported in the Supplementary Materials.

Search strategy
The following electronic databases were systematically searched from inception to November 2025: PubMed, Embase (OVID platform), Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (OVID platform), and Google Scholar. The complete search strategies, including MeSH terms, Emtree terms, keywords, Boolean operators, truncation, and field tags, are provided in Table 1. For PubMed and Embase, searches were limited to human studies and the English language. For CENTRAL and MEDLINE, searches were limited to randomized controlled trials. For Google Scholar, the first 500 records sorted by relevance were searched using a simplified search string ('exercise AND depression AND (remission OR medication OR treatment)') due to platform limitations on complex Boolean searching¹⁹.

In addition to database searches, the following supplementary searches were conducted: hand-searching of reference lists of all included studies and relevant systematic reviews (snowball searching), citation tracking of key included studies using Google Scholar and Web of Science, hand-searching of key journals (Mental Health and Physical Activity, Journal of Affective Disorders, Depression and Anxiety, and Psychosomatic Medicine) for the years 2020–2025, and searching of clinical trial registries (ClinicalTrials.gov, WHO ICTRP) for unpublished or ongoing trials using the search terms 'exercise' AND 'depression'. The complete search history, including the number of records retrieved at each step for each database, is provided in Supplementary Table 1. The PRISMA 2020 search reporting checklist was followed (Supplementary File 1).

Selection process

All identified records were exported to EndNote 20 for duplicate removal. Following deduplication, two independent reviewers performed a calibration exercise on a random sample of 100 records to ensure consistent application of eligibility criteria. After confirming acceptable agreement (κ ≥ 0.80), the reviewers independently screened titles and abstracts of all remaining records against the prespecified eligibility criteria. Records deemed potentially relevant by either reviewer were sent for full-text review. Full-text articles were obtained and independently assessed by the same two reviewers. Reasons for exclusion at the full-text stage were documented according to PRISMA guidelines (e.g., no exercise intervention, no depression diagnosis, no control group, non-comparative design, duplicate publication). Disagreements at either screening stage were resolved through discussion; if consensus could not be reached, the corresponding author made the final decision. Inter-rater agreement for full-text inclusion was calculated using Cohen’s kappa statistic. Although EndNote 20 was used for initial duplicate removal, additional duplicates that were not detected by the software (e.g., due to slight variations in titles, author names, or journal abbreviations) were identified and removed during manual title/abstract screening by the two independent reviewers.

The screening and selection process is summarized in the PRISMA 2020 flow diagram (Figure 1), which includes the number of records identified, duplicates removed, records screened, reports sought for retrieval, reports assessed for eligibility, and studies included, with specific exclusion reasons at each stage. Google Scholar was searched using the simplified string 'exercise AND depression AND (remission OR medication OR treatment)' with the following settings: sort by relevance, exclude citations, and include patents. The first 500 records were screened. The search was conducted on November 15, 2025, at 10;00 AM GMT, with no personalization enabled, and was repeated on November 16, 2025, to verify consistency.

Data extraction

Two reviewers independently extracted data from each included study using a standardized, pilot-tested data extraction form. The following information was collected: first author name, publication year, country where the study was conducted, sample size (total, exercise group, control group), participant characteristics (age, depression diagnosis or screening method, baseline depression severity), intervention details (exercise mode, intensity, frequency, duration, supervision, format), control group description, depression outcome measures (scale name and range), timing of outcome assessment, and statistical results (means, standard deviations, effect estimates, confidence intervals, p-values)²⁰. Disagreements between reviewers were resolved by discussion or by consulting the corresponding author.

Data items

Data were independently gathered based on a valuation of exercise intervention for depression symptoms when a study produced different results.

Risk of bias assessment

Two authors independently assessed the risk of bias for each included study using the Cochrane RoB 2 tool for randomized controlled trials (version of August 2019). The RoB 2 tool evaluates five domains of bias arising from the randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result. For each domain, reviewers assigned a judgment of ‘low-risk of bias,’ ‘some concerns,’ or ‘high risk of bias.’ An overall risk-of-bias judgment was then derived for each study according to the RoB 2 algorithms ‘low-risk’ (all domains low-risk), ‘some concerns’ (at least one domain with some concerns but no high-risk domains), or ‘high risk’ (any domain rated high risk or multiple domains with some concerns). Disagreements between reviewers were resolved through discussion, with the corresponding author arbitrating when necessary. Studies were not excluded based on risk-of-bias judgments; instead, sensitivity analyses were planned to restrict the meta-analysis to studies with 'low-risk' or 'low-risk + some concerns' overall judgments to examine the robustness of the findings. Inter-rater agreement for overall risk-of-bias judgments was calculated using Cohen’s kappa²¹.

Subgroup analyses (moderator analyses)

To explore potential sources of heterogeneity and identify moderators of exercise efficacy, a series of a priori subgroup analyses based on clinically and methodologically relevant variables was conducted. Subgroup analyses were performed only for outcomes with at least 10 studies per subgroup (to ensure adequate statistical power). The following subgroup variables were prespecified.

Exercise characteristics

Exercise mode as aerobic (e.g., walking, running, cycling) vs. resistance (e.g., weight training) vs. mixed (aerobic + resistance) vs. other (yoga, dance, mindfulness-based movement).

Exercise intensity as light (e.g., gentle walking, stretching) vs. moderate (e.g., brisk walking, moderate cycling) vs. vigorous (e.g., running, high-intensity interval training) – classified using standard heart rate or perceived exertion criteria reported in each study.

Exercise duration (weeks) as short (≤8 weeks) vs. medium (9–12 weeks) vs. long (≥13 weeks).

Supervision as supervised (exercise sessions led by an instructor, trainer, or therapist) vs. unsupervised (home-based or self-directed with no direct supervision).

Format as group-based vs. individual (home or one-on-one).

Population characteristics

Depression diagnosis was categorized as either major depressive disorder (MDD), diagnosed through a structured clinical interview such as the structured clinical interview for DSM disorders (SCID) or the mini international neuropsychiatric interview (MINI), or elevated depressive symptoms identified using validated screening tools based on established cutoff scores, including the center for epidemiologic studies depression scale (CES-D ≥ 16), Beck depression inventory (BDI ≥ 14), or patient health questionnaire-9 (PHQ-9 ≥ 10). Age group was classified as adults (18–59 years) or older adults (≥60 years). Baseline depression severity was categorized as moderate or severe according to standard cutoff scores for each assessment scale, with moderate depression defined, for example, as a Hamilton Depression Rating Scale (HAM-D) score of 14–18 or a BDI score of 14–19, and severe depression defined as a HAM-D score of ≥19 or a BDI score of ≥20.

Study design characteristics

Control group type was categorized as either passive, including waitlist, no-treatment, or usual care control conditions, or active, including attention control interventions, pharmacotherapy, or psychotherapy. Publication year was classified into three periods—pre-2010, 2010–2019, and 2020–2025—to examine potential temporal trends in study findings. Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool and categorized as low-risk, some concerns, or high risk. Sample size was classified as small (n < 50 total participants), medium (50–99 participants), or large (≥100 participants). Control group type was categorized as passive (waitlist, usual care, no intervention) – these controls do not provide an active therapeutic alternative, so the effect of exercise may be larger due to expectation or attention effects; and active (attention control, pharmacotherapy, psychotherapy) – these controls provide a non‑exercise intervention of credible therapeutic value, yielding a more conservative estimate of exercise’s specific effect. A significantly larger effect for passive vs. active controls (p for interaction < 0.10), as hypothesized, was confirmed in the results (see Table 3).

Statistical methods for subgroup analyses

For each subgroup analysis, studies within each subgroup were pooled using a random-effects model²². To compare subgroups, mixed-effects meta-regression or subgroup interaction tests were used. Specifically, the Q-statistic for between-subgroup differences was calculated, and the associated p-value for interaction is reported. A p-value < 0.10 (rather than 0.05) was considered statistically significant for subgroup differences, acknowledging the low power of interaction tests in meta-analyses. Multiple-comparison adjustment (12 subgroup analyses) was not performed; therefore, subgroup findings should be interpreted as exploratory.

Sensitivity analyses

To assess the robustness of the primary findings, the following prespecified sensitivity analyses were conducted. Model choice as re-analyzed both outcomes using a fixed-effect model (inverse variance method) to compare with the primary random-effects results, exclusion of high-risk-of-bias studies as excluded studies with an overall RoB 2 judgment of ‘high risk of bias’ (n = 17), and re-analyzed the remaining studies (low-risk + some concerns), exclusion of multi-arm trials as excluded studies where multiple exercise arms were combined or where a single control group was used for multiple comparisons (n = 9) and re-analyzed only two-arm trials, exclusion of studies with imputed or assumed data as excluded studies where standard deviations for change scores were assumed (r = 0.50) rather than reported (n = 6), exclusion of pre-CONSORT studies as excluded studies published before 2001 (n = 5) to assess whether improved reporting standards influenced effect estimates, influence analysis (leave-one-out) as performed a leave-one-out meta-analysis, sequentially removing each study and recalculating the pooled effect to identify influential studies (defined as those whose removal changes the point estimate by >10% or moves the confidence interval beyond the original bounds), and long-term follow-up analysis as for studies reporting follow-up data at ≥6 months post-intervention (n = 6), these data were separately pooled to examine the durability of exercise effects, without mixing with primary endpoint (post-intervention) data. All sensitivity analyses were conducted using random-effects models unless otherwise specified. Results of sensitivity analyses are reported in the Results section and supplementary materials. Any deviation from these prespecified analyses is reported transparently.

Extraction of continuous outcome data (depression scores)

For each included study, the mean depression score and its standard deviation (SD) for both exercise and control groups were extracted at the primary endpoint (defined as the time point closest to the end of the exercise intervention). To maximize consistency across studies, the following hierarchical extraction rule was applied: adjusted effect estimates (e.g., ANCOVA-derived between-group differences with 95% CIs or SEs) were prioritized when available, as they account for baseline imbalances and typically provide the least biased estimate of intervention effect. Change-from-baseline scores (post-minus-pre or percentage change) and their SDs were extracted when adjusted effects were not reported. If the SD of change scores was not directly reported, it was calculated using the formula:

   (1)

where a conservative correlation coefficient of r = 0.5 was assumed unless the study provided a reported or imputable correlation. Post-intervention scores only (without adjustment or change scores) were extracted when neither adjusted effects nor change scores were available. This was the least preferred option because it does not account for potential baseline differences between groups. Conversion from other statistics, as if means and SDs were not reported directly, available statistics (medians and IQRs, t-statistics, F-statistics, p-values, or 95% CIs) were converted to means and SDs using standard formulas from the Cochrane Handbook (Chapter 6). Studies reporting only medians and ranges were included only if sample sizes were large enough (n ≥ 25 per group) to assume approximate normality, or if the study authors provided means and SDs upon request.

Multiple time points as for studies reporting multiple follow-up time points, the time point closest to the end of the active intervention period (typically 8–12 weeks) was extracted. Long-term follow-up data (≥6 months post-intervention) were extracted separately for a planned secondary analysis of durability, but these data were not pooled with primary endpoint data. Multiple depression scales. When a study reported more than one depression scale (e.g., both HAM-D and BDI), clinician-rated scales (HAM-D, MADRS) were prioritized over self-report scales (BDI, CES-D, PHQ-9, GDS) because clinician-rated scales are considered the gold standard in depression trials. If both were reported, the primary outcome measure as defined by the study authors was extracted. Imputation of missing SDs as if standard deviations were missing and could not be calculated from available statistics; they were imputed by taking the average SD from studies with similar sample sizes and the same depression scale. Sensitivity analyses were conducted, excluding studies with imputed SDs, to assess the impact of this imputation. All data extraction decisions were performed independently by two authors using a standardized data extraction form. Discrepancies were resolved by discussion or by the corresponding author. The extraction rule and any deviations were recorded.

Effect measures

For the dichotomous outcome (depression remission), odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. For the continuous outcome (depression severity scores), included studies were anticipated to use different depression rating scales (e.g., Hamilton Depression Rating Scale, Beck Depression Inventory, PHQ-9, CES-D, Geriatric Depression Scale). Although included studies used different depression rating scales, the standard mean difference (SMD) was reported because all scales had established conversion equations to HAM-D.

Statistical synthesis

For the dichotomous outcome (depression remission), pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. For the continuous outcome (depression severity scores), pooled standardized mean differences (SMDs, Hedges' g) with 95% CIs were calculated because included studies used different depression rating scales. Given the anticipated clinical and methodological diversity across studies (variations in exercise protocols, populations, control conditions, and outcome measures), a random-effects model (DerSimonian and Laird method) was chosen a priori for all primary analyses²². Heterogeneity was quantified using the I² statistic, interpreted using Cochrane Handbook criteria as next 0–40% (might not be important), 30–60% (moderate heterogeneity), 50–90% (substantial heterogeneity), and 75–100% (considerable heterogeneity). The between-study variance (tau²) was also estimated, and 95% prediction intervals for the pooled effects were calculated where appropriate.

Statistical analysis and heterogeneity

Due to the expected clinical and methodological diversity across included studies (including variations in exercise type, intensity, duration, supervision, population characteristics, depression severity, control conditions, and depression measurement scales), a random-effects model (DerSimonian and Laird method) was chosen a priori for all primary analyses²². The random-effects model assumes that the true effect varies across studies and provides a more conservative estimate with wider confidence intervals, which is appropriate given the anticipated heterogeneity.

Assessment of heterogeneity

Heterogeneity was quantified using the I² statistic, which represents the percentage of total variation across studies due to true heterogeneity rather than chance. I² values were interpreted as follows: 0–40% (might not be important); 30–60% (moderate heterogeneity); 50–90% (substantial heterogeneity); 75–100% (considerable heterogeneity), as in Cochrane Handbook criteria. In addition to I², the between-study variance (tau²) and report 95% prediction intervals for the pooled effect when appropriate were estimated.

Model selection justification

A fixed-effect model was not used for any primary analysis because the studies are not functionally identical (they vary in exercise protocols, populations, and outcome measures), the assumption of a single true effect shared by all studies is implausible in exercise-depression research, and even when I² appears low (e.g., I² = 48% for remission), clinical diversity alone justifies a random-effects approach. For completeness, sensitivity analyses using a fixed-effect model were also conducted to examine whether model choice influenced the conclusions; these results are reported in the supplementary materials.

Publication bias assessment

Publication bias and small-study effects were assessed using both visual inspection of funnel plots and Egger's linear regression test. For each outcome, funnel plots were generated showing the effect size (log odds ratio for remission; standardized mean difference for depression scores) against its standard error. For the quantitative assessment, Egger's test regresses the standardized effect estimate against its precision (the inverse of the standard error). A statistically significant intercept (p < 0.10 in meta-analyses with ≥10 studies) suggests the presence of funnel plot asymmetry, which may indicate publication bias or small-study effects. Conversely, p ≥ 0.10 indicates no statistical evidence of such bias.

Prediction intervals

For the primary random-effects meta-analysis, 95% prediction intervals were calculated, which estimate the range within which the true effect of a future study would fall. Wide prediction intervals indicate that the effect of exercise may vary substantially across settings and populations, with important clinical implications. For multi-arm studies in which multiple exercise arms were combined into a single group, the formulas in the Cochrane Handbook were used to calculate combined means, standard deviations, and sample sizes. For studies that used a single control arm across multiple exercise comparisons, double counting was avoided by dividing the control group sample size by the number of exercise arms when calculating effect sizes. All analyses were conducted using Reviewer Manager Version 5.3, with multi-arm handling verified by two authors independently.

Number needed to treat (NNT) calculation

The number needed to treat (NNT) was calculated from the pooled odds ratio (OR) for remission using the formula

where CER (control event rate) was the pooled remission rate across all included studies. NNT was also calculated using the alternative method proposed by Furukawa and Leucht (2011), which converts Cohen's d (from SMD) to NNT using the area under the normal curve. NNT values were calculated for the primary analysis (all studies), for subgroups (low-risk of bias studies, MDD-only studies, supervised exercise studies), and for comparison with published NNT values for psychotherapy and antidepressant medication. An NNT of ≤ 10 was considered clinically meaningful.

Conversion to clinically familiar metrics (BDI and HAM-D)

To aid clinical interpretability, the pooled standardized mean difference (SMD) for depression scores was converted into estimated mean differences on two commonly used depression scales: the Beck Depression Inventory (BDI, range 0–63) and the Hamilton Depression Rating Scale (HAM-D, range 0–52). Conversion used the following formula

where SD_{pooled, reference} was the pooled baseline standard deviation from studies that used the BDI (n = 8 studies) or HAM-D (n = 16 studies), respectively. This approach assumes that the SMD effect size is consistent across scales. The observed mean differences from these studies are also reported as a sensitivity check. A change of ≥3 points on the BDI or HAM-D was considered clinically meaningful per NICE guidelines⁵.

Comparison with established depression treatments

To contextualize the effect of exercise relative to other first-line depression treatments, the pooled NNT for exercise was compared with published NNT values from recent high-quality meta-analyses. Psychotherapy, as Cuijpers et al. (2020) reported, has an NNT of 2.5 for psychotherapy across all age groups. Antidepressant medication, as Cipriani et al. (2018) reported, has an NNT of 4.3 for medication vs. placebo. These comparisons are descriptive and not based on head-to-head trials. Exercise data were not pooled with psychotherapy or medication data, and differences in study populations, outcome definitions, and time points limit direct comparability.

Assessment of reporting bias (publication bias)

Funnel plots for each outcome (remission and depression score), funnel plots showing the effect size (log odds ratio for remission; standardized mean difference for depression scores) against its standard error were generated. Asymmetry in the funnel plot may indicate publication bias, small-study effects, or heterogeneity. Egger's regression test, also known as Egger's linear regression test, was conducted to formally assess funnel plot asymmetry. Egger's test regresses the standardized effect estimate on its precision (the inverse of the standard error). A statistically significant intercept (p < 0.10 for Egger's test, as recommended by the Cochrane Handbook for outcomes with fewer than 10 studies, or p < 0.05 for larger meta-analyses) suggests the presence of small-study effects or publication bias. Conversely, p ≥ 0.05 (or p ≥ 0.10) indicates no statistically significant evidence of such bias. Interpretation caution as Funnel plot asymmetry is not synonymous with publication bias; it may also arise from true heterogeneity, differences in study quality, or chance, and the results should be interpreted accordingly²³.

Certainty of evidence (GRADE assessment)

The overall certainty of evidence for each outcome (remission and depression score) was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Two authors independently rated the certainty and resolved disagreements by discussion. The GRADE approach considers five domains that can lower certainty: risk of bias (based on RoB 2 assessments, including the proportion of studies with low-risk, some concerns, or high risk), inconsistency (based on the I² statistic, prediction intervals, and overlap of confidence intervals), indirectness (based on differences between study populations, interventions, comparators, and outcomes relative to the review question), imprecision (based on optimal information size and whether 95% confidence intervals cross clinically important thresholds, such as an odds ratio of 1.0 for remission or a standardized mean difference of 0.2 for a small effect on depression scores), and publication bias (based on funnel plot asymmetry and Egger's test). Certainty was graded as follows High (Further research is very unlikely to change confidence in the effect estimate); Moderate (Further research is likely to have an important impact on confidence and may change the estimate); Low (Further research is very likely to have an important impact on confidence and is likely to change the estimate); and Very low (Any estimate of effect is very uncertain). Certainty assessments were performed separately for remission (dichotomous outcome) and depression scores (continuous outcome).

Results

Study selection

The PRISMA 2020 flow diagram (Figure 1) summarizes the study selection process. Database searches identified 10,123 records (Cochrane Library: n = 1,845; Embase: n = 2,567; Google Scholar: n = 3,210; MEDLINE via OVID: n = 1,892; PubMed: n = 609). After removing 1,018 duplicate records, 9,105 unique records remained for screening. Discrepancy between stated and applied inclusion criteria for control groups. The innovation section initially stated that studies with active psychological interventions or stretching/relaxation controls were excluded. However, during the review process, excluding active comparators would limit clinical generalizability and remove important studies (e.g., exercise vs. pharmacotherapy). Therefore, the final eligibility criteria (as documented in the Methods) accepted both passive and active non‑exercising controls. This discrepancy is transparently reported here and in the discussion (Limitations). To examine the impact of including active comparators, prespecified subgroup analyses stratifying by control type (passive vs. active; see Table 3) and sensitivity analyses excluding active controls altogether were conducted.

Title and abstract screening

Two reviewers independently screened titles and abstracts of all 9,105 records. A calibration exercise on 100 records (κ = 0.92) confirmed consistent application of eligibility criteria. Of these, 8,997 records were excluded because they clearly did not meet the inclusion criteria;

Not related to depression (n = 3,644); No exercise intervention (n = 3,015); Animal or in vitro studies (n = 556); Reviews, commentaries, editorials, or conference abstracts (n = 1,102); Duplicate publications not identified during the initial EndNote deduplication process but subsequently detected during manual title/abstract screening (n = 153); and Non-English language without available translation (n = 527).

Full-text retrieval

Full-text reports for the remaining 108 records were assessed for eligibility.

Full-text exclusion

After detailed assessment, 68 full-text articles were excluded for the following reasons; No non-exercising control group (e.g., exercise vs. exercise only, or no control) (n = 10); No depression outcome measure (n = 9); No original data (e.g., protocol only, duplicate publication of same cohort) (n = 9); No structured exercise intervention (e.g., physical activity advice only, no prescribed program) (n = 8); Population did not have depression (e.g., healthy volunteers, other psychiatric disorders) (n = 17); Insufficient data for effect size calculation (means/SD not reported and not obtainable from authors) (n = 9); and non-randomized design (observational, uncontrolled) (n = 6).

Final inclusion

Forty randomized controlled trials met all eligibility criteria and were included in the meta-analysis. The characteristics of these 40 studies are presented in Supplementary Table 1. Forty studies were included overall; 37 contributed to remission analysis and 24 to depression severity analysis. A total of 2,667 participants with depression were included across the 40 studies (1,415 in exercise groups, 1,252 in control groups)^{24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,
58,59,60,61,62,63}. The sample size ranged from 16 to 266 participants. These limitations may affect the significance of the findings.

Extraction of continuous outcome data
Across the 40 included studies, the following types of effect estimates were extracted: post-intervention scores only (n = 23, 52.3%), change-from-baseline scores (n = 14, 31.8%), and adjusted effect estimates from ANCOVA or similar models (n = 7, 15.9%). No studies required direct imputation of missing standard deviations using external data (e.g., borrowing SDs from other studies), as all studies provided sufficient raw data—baseline and post-intervention means and SDs—to calculate the required effect estimates. For studies reporting multiple follow-up time points (n = 11), the primary endpoint at the end of the intervention period (median 12 weeks, range 3–16 weeks) was extracted. Long-term follow-up data (≥6 months) were available in 6 studies and are reported separately in a sensitivity analysis. When compared to the control group, exercise demonstrated significantly higher remission (OR, 2.40; 95% CI, 1.97–2.93, p < 0.001) with low heterogeneity (I² = 49%), this indicates that in a future study conducted in a similar setting, the true OR for remission could be as low as 1.28 (modest benefit) or as high as 4.73 (large benefit), reflecting moderate uncertainty, and lower depression score (SMD, -0.96; 95% CI, -1.27–-0.65, p < 0.001) with high heterogeneity (I² = 87%) in patients with depression, as shown in Figures 2 and 3. The substantial heterogeneity (I² = 87%) likely reflects, in part, this scale diversity. This wide interval crosses zero, indicating that in some future settings or populations, exercise might not reduce depression scores or could even be detrimental. This finding underscores the need for individualized prescription of exercise for depression.

Number needed to treat (NNT)

The pooled remission rate in control groups (CER) was 32.4% (430/1326). Using the OR for remission (2.40), the calculated NNT for the primary analysis was 2.1 (95% CI, 1.7–2.8). This means that approximately 2 patients need to receive exercise treatment for each additional patient who achieves remission compared to the control. Using the alternative method based on the primary SMD (converted to Cohen's d = 0.96 in absolute value), the NNT was 2.0, consistent with the OR-based estimate. Subgroup NNT values were as follows; low-risk-of-bias studies (n = 12); NNT = 2.8 (95% CI, 2.1–4.2); MDD-only studies (n = 24); NNT = 1.9 (95% CI, 1.5–2.6); and supervised exercise studies (n = 35); NNT = 1.6 (95% CI, 1.3–2.1)

Comparison with established treatments;

The NNT for exercise in the primary analysis (2.1) was lower (more favorable) than published NNTs for psychotherapy (2.5) and antidepressant medication (4.3). However, these comparisons are indirect and should be interpreted with caution due to differences in study populations, outcome definitions, and time points.

Scale-specific mean differences (BDI and HAM-D)

Using the pooled SMD (–0.96) and the pooled baseline standard deviations from studies using each scale, Beck Depression Inventory (BDI); Based on 8 studies (n = 292) with a pooled baseline SD of 10.3, the estimated mean difference was –6.5 (95% CI, –9.2 to –3.8) BDI points. The observed mean differences in these 8 studies ranged from –4.2 to –8.9, all favoring exercise. Hamilton Depression Rating Scale (HAM-D); Based on 16 studies (n = 634) with a pooled baseline SD of 4.5, the estimated mean difference was –4.7 (95% CI, –6.9 to –2.5) HAM-D points. The observed mean differences in these 16 studies ranged from –3.1 to –6.8, all favoring exercise. Both estimated differences exceed the NICE threshold for clinical significance (≥3 points on BDI or HAM-D), suggesting that exercise produces clinically meaningful reductions in depressive symptoms.

Risk-of-bias assessment results

A summary of the RoB 2 assessments for all 40 included studies is presented in Table 2. Across the five domains, the proportion of studies judged as ‘low-risk of bias,’ ‘some concerns,’ and ‘high risk of bias’ was as follows: risk of bias assessment demonstrated variable methodological quality across the five RoB 2 domains. For Domain 1 (randomization process), 24 studies (60%) were judged as low-risk of bias, 10 studies (25%) had some concerns, and 6 studies (15%) were considered at high risk. In Domain 2 (deviations from intended interventions), 15 studies (37.5%) were rated as low-risk, 15 studies (37.5%) had some concerns, and 10 studies (25%) were classified as high risk. For Domain 3 (missing outcome data), 18 studies (45.0%) were assessed as low-risk, while 12 studies (30%) had some concerns, and 10 studies (25%) were at high risk. Domain 4 (outcome measurement) demonstrated the most favorable ratings, with 27 studies (67.5%) categorized as low-risk, 9 studies (22.5%) as having some concerns, and only 4 studies (10%) as high risk. Finally, for Domain 5 (selection of the reported result), 21 studies (52.5%) were rated as low-risk, 14 studies (35%) had some concerns, and 5 studies (12.5%) were judged to be at high risk of bias. For overall RoB 2 judgments; 12 studies (30%) were rated as ‘low-risk of bias’ (all five domains low-risk), 13 studies (32.5%) as ‘some concerns’ (at least one domain with some concerns but no high-risk domains), and 15 studies (37.5%) as ‘high risk of bias’ (any domain rated high risk or multiple domains with some concerns).

The most common reasons for ‘high risk’ judgments were: inadequate blinding of participants and personnel (Domain 2, 22.7%), high or unbalanced dropout rates without appropriate imputation (Domain 3, 22.7%), and inadequate allocation concealment (Domain 1, 13.6%). Studies published before 2001 (the pre-CONSORT era, n = 5) accounted for 4 of the 15 ‘high risk’ judgments. Inter-rater agreement for overall risk-of-bias judgments was substantial (κ = 0.79; 95% CI, 0.68–0.88). No studies were excluded based on risk-of-bias judgments; instead, sensitivity analyses restricted to studies with ‘low-risk’ or ‘low-risk + some concerns’ are reported below.

Subgroup analyses

Table 3 presents the results of all prespecified subgroup analyses for the remission outcome (OR) and depression score outcome (SMD). Key findings include: Exercise mode as both aerobic (OR, 2.54; 95% CI, 2.01–3.21; n = 24) and resistance (OR, 2.38; 95% CI, 1.72–3.29; n = 8) training, showed significant effects, with no significant difference between modes (p for interaction = 0.68). Mixed aerobic + resistance training showed a smaller effect (OR, 1.92; 95% CI, 1.31–2.81; n = 6), though the interaction was not significant (p = 0.21). Supervision as supervised exercise (OR, 2.71; 95% CI, 2.18–3.36; n = 31) produced larger effects than unsupervised exercise (OR, 1.88; 95% CI, 1.34–2.64; n = 9), and the difference was statistically significant (p for interaction = 0.04). Control group type as passive controls (waitlist/usual care) yielded larger effects (OR, 2.89; 95% CI, 2.31–3.61; n = 24) than active controls (active non-exercise controls were allowed) (attention control/pharmacotherapy/psychotherapy; OR, 1.79; 95% CI, 1.34–2.38; n = 16; p for interaction = 0.02). Depression diagnosis, as studies requiring a formal MDD diagnosis (OR, 2.32; 95% CI, 1.82–2.95; n = 20) showed similar effects to studies using screening tool cutoffs (OR, 2.61; 95% CI, 1.99–3.42; n = 20; p for interaction = 0.41). Risk of bias as low-risk-of-bias studies (OR, 2.08; 95% CI, 1.52–2.85; n = 12) showed smaller effects than studies with some concerns (OR, 2.68; 95% CI, 1.94–3.70; n = 13) or high risk (OR, 2.54; 95% CI, 1.81–3.56; n = 15), but the differences were not statistically significant (p for interaction = 0.34). Sample size as larger studies (n ≥ 100) showed smaller effects (OR, 1.96; 95% CI, 1.45–2.65; n = 8) than medium (OR, 2.61; 95% CI, 1.99–3.42; n = 16) or small studies (OR, 2.58; 95% CI, 1.86–3.58; n = 16), suggesting potential small-study effects, though the interaction was not significant (p = 0.28). Egger's test did not detect publication bias (p = 0.87), but this pattern is consistent with some degree of bias or heterogeneity.

For depression scores (SMD), findings were largely consistent with those for remission, although wide confidence intervals and high heterogeneity limited interpretability for several subgroups. Detailed results for all subgroup analyses are provided in Table 3. Although aerobic exercise was the most frequently studied modality (28 trials), resistance training and mixed protocols also showed significant effects, with overlapping confidence intervals suggesting no clear superiority of one modality over another.

Certainty of evidence (GRADE)

Using the GRADE framework, the certainty of evidence for depression remission was rated as moderate (Table 3). Certainty was downgraded by one level for serious risk of bias (37.5% of studies with overall ‘high risk’ per RoB 2). Inconsistency was not serious (I² = 48%; prediction interval did not cross 1.0), indirectness was not present, imprecision was not serious (optimal information size met), and publication bias was not detected. This indicates moderate confidence that exercise increases depression remission compared to control conditions; however, further high-quality research may change this estimate. For depression severity scores (SMD), the certainty of evidence was rated as low (Table 4). Certainty was downgraded by one level for serious risk of bias (same reason as above) and by an additional level for very serious inconsistency (I² = 87%; 95% prediction interval −1.42 to 0.20, which crosses the null effect). The wide prediction interval indicates that in some future settings, exercise might not reduce depression scores or could even be detrimental. Low certainty means that confidence in the effect estimate is limited, and the true effect may be substantially different from the point estimate.

Sensitivity analysis by extraction type

To assess whether the choice of extraction method influenced the pooled effect size, studies were stratified by the type of effect estimate extracted. There was no statistically significant difference between these subgroups (p for interaction = 0.54), suggesting that the extraction method did not systematically bias the results. However, all subgroups exhibited substantial heterogeneity, with the lowest heterogeneity observed in the adjusted-effects subgroup (I² = 72%).

The use of stratified models to inspect the effects of certain components was not possible owing to the lack of data, such as gender, ethnicity, and age, on comparison outcomes. Visual inspection of the funnel plot for remission (Figure 4) showed approximate symmetry. The Egger regression test for remission yielded a p-value of 0.87, indicating no statistically significant evidence of small-study effects or publication bias for this outcome. For depression scores (Figure 5), the funnel plot appeared roughly symmetrical, with an Egger test p-value of 0.68, similarly suggesting no evidence of publication bias. However, given the high heterogeneity for depression scores (I² = 87%), funnel plot asymmetry due to heterogeneity rather than bias cannot be ruled out. The RoB 2 assessment revealed that 15 of 40 studies (37.5%) were judged as having an overall ‘high risk of bias,’ primarily due to inadequate blinding of participants and personnel (Domain 2), incomplete outcome data (Domain 3), and inadequate allocation concealment (Domain 1). An additional 13 studies (32.5%) had ‘some concerns.’ Only 12 studies (30%) were rated as overall ‘low-risk of bias.’ Selective reporting (Domain 5) was judged as low-risk for the majority of studies (56.8%), suggesting that reporting bias was not a major concern.

Handling of multi-arm trials

Of the 40 included studies, 9 (20.5%) had multi-arm designs requiring special handling. For studies with multiple exercise arms compared to a single control group (n = 5), exercise arms were combined to avoid double-counting control participants. For studies with both exercise and multiple non-exercise comparator arms (n = 4), the most conservative non-exercising control was selected (prioritizing waitlist or usual care over pharmacotherapy or psychotherapy). A sensitivity analysis excluding all multi-arm studies yielded similar results to the primary analysis (remission: OR, 2.38; 95% CI, 1.94–2.91 vs. primary OR 2.46; depression SMD: −0.58; 95% CI, −0.87 to −0.29 vs. primary SMD −0.96), indicating that the handling of multi-arm trials did not substantially bias the findings.

DATA AVAILABILITY:

The datasets analyzed during the current study are available from

https;//zenodo.org/records/19980462. The new PRISMA checklist is attached as Supplementary File 1.

FIGURES AND TABLES LEGENDS:

Figure 1: PRISMA flow diagram of the study selection process. The diagram shows the number of records identified, screened, assessed for eligibility, and included in the meta-analysis. Boxes represent sequential stages of the review process: identification, screening, eligibility assessment, and inclusion. Arrows indicate the flow of records through each stage. Reasons for exclusion and corresponding numbers are provided in the exclusion boxes. Abbreviations: n = number of records or studies; PRISMA = preferred reporting items for systematic reviews and meta-analyses. Please click here to view a larger version of this figure.

Figure 2: Forest plot of the effect of exercise versus control on depression remission (odds ratio). Each horizontal line represents an individual study (n = 37). The square at the center of each line represents the point estimate (odds ratio, OR), with the size of the square proportional to the study's weight in the pooled analysis (inverse variance method) under a random‑effects model (DerSimonian and Laird). The horizontal line represents the 95% confidence interval (CI). The vertical dashed line at OR = 1.0 represents the line of no effect. The diamond at the bottom represents the pooled effect estimate; the center of the diamond is the pooled OR (2.40), and the width represents the 95% CI (1.97 to 2.93). Heterogeneity statistics (I² = 49%) and the p‑value for the overall effect (p < 0.001) are shown below the diamond. No fixed‑effect model was used for this primary analysis. Abbreviations: OR = odds ratio; CI = confidence interval; Random‑effects model (DerSimonian and Laird). Please click here to view a larger version of this figure.

Figure 3: Forest plot of the effect of exercise versus control on depression severity (standardized mean difference, SMD). Each horizontal line represents an individual study (n = 24). The square at the center of each line represents the point estimate (SMD, Hedges' g), with the size of the square proportional to the study's weight in the pooled analysis (inverse variance method). The horizontal line represents the 95% confidence interval (CI). Negative SMD values favor exercise (reduced depression severity). The vertical solid line at SMD = 0 represents the line of no effect. The diamond at the bottom represents the pooled effect estimate using a random-effects model (DerSimonian and Laird method); the center of the diamond is the pooled SMD (−0.96), and the width represents the 95% CI (−1.27 to −0.65). Heterogeneity statistics (I² = 87%, tau² = 0.46) and the p-value for the overall effect (p < 0.001) are shown below the diamond. Abbreviations: SMD = standardized mean difference (Hedges' g); CI = confidence interval; IV = inverse variance; Random = random-effects model. Please click here to view a larger version of this figure.

Figure 4: Funnel plot for remission (odds ratio). Each point represents an individual study (n = 37). The vertical line represents the pooled effect estimate (OR = 2.40). The diagonal lines represent pseudo-95% confidence intervals. The approximate symmetry of the plot and Egger's test (p = 0.87) suggests no evidence of publication bias or small-study effects. Please click here to view a larger version of this figure.

Figure 5: Funnel plot assessing potential publication bias for the depression severity outcome (standardized mean difference, SMD). Each circle represents an individual study comparison (n = 24). The vertical line indicates the pooled effect estimate (SMD = −0.96). Studies are plotted by effect size (x-axis) and standard error (SE; y-axis). Larger studies with smaller standard errors appear toward the top of the plot, whereas smaller studies appear toward the bottom. Visual inspection suggests approximate symmetry, although dispersion is evident because of substantial between-study heterogeneity (I² = 87%). Egger's regression test was not statistically significant (intercept = −0.25, 95% CI −1.08 to 0.58; p = 0.68), indicating no statistical evidence of small-study effects. Abbreviations: SMD = standardized mean difference; SE = standard error; CI = confidence interval. Please click here to view a larger version of this figure.

Database (platform)	Search date	Complete search syntax				Limits/filters
PubMed	Nov-25	("exercise"[MeSH Terms] OR "exercise"[tiab] OR "physical activity"[tiab] OR "aerobic"[tiab] OR "resistance training"[tiab] OR "strength training"[tiab] OR "yoga"[tiab] OR "walking"[tiab]) AND ("depression"[MeSH Terms] OR "depressive disorder"[MeSH Terms] OR "depression"[tiab] OR "depressive symptoms"[tiab] OR "major depressive disorder"[tiab] OR "dysthymia"[tiab]) AND ("remission"[MeSH Terms] OR "remission"[tiab] OR "antidepressant agents"[MeSH Terms] OR "medication"[tiab] OR "pharmacotherapy"[tiab] OR "treatment outcome"[MeSH Terms])				Humans; English language; no date limits
Embase (OVID)	Nov-25	(exp exercise/ or exp physical activity/ or (exercise$ or physical activity$ or aerobic$ or resistance training or strength training or yoga or walking).ti,ab.) AND (exp depression/ or exp major depression/ or (depression$ or depressive symptoms or major depressive disorder or dysthymia).ti,ab.) AND (exp remission/ or exp drug therapy/ or (remission$ or medication$ or pharmacotherapy$ or treatment outcome$).ti,ab.)				Humans; English language; articles in press; no date limits
Cochrane Central Register of Controlled Trials (CENTRAL)	Nov-25	#1 MeSH descriptor: [Exercise] explode all trees OR MeSH descriptor: [Physical Activity] explode all trees OR (exercise* OR "physical activity" OR aerobic OR "resistance training" OR "strength training" OR yoga OR walking):ti,ab,kw				Trials only (CENTRAL default); no date limits
		#2 MeSH descriptor: [Depression] explode all trees OR MeSH descriptor: [Depressive Disorder] explode all trees OR (depression* OR "depressive symptoms" OR "major depressive disorder" OR dysthymia):ti,ab,kw
		#3 MeSH descriptor: [Remission] explode all trees OR MeSH descriptor: [Antidepressive Agents] explode all trees OR (remission* OR medication* OR pharmacotherapy* OR "treatment outcome"):ti,ab,kw
		#4 #1 AND #2 AND #3
MEDLINE (OVID)	Nov-25	(exp exercise/ or exp physical activity/ or (exercise$ or physical activity$ or aerobic$ or resistance training or strength training or yoga or walking).ti,ab.) AND (exp depression/ or exp depressive disorder/ or (depression$ or depressive symptoms or major depressive disorder or dysthymia).ti,ab.) AND (exp remission/ or exp antidepressive agents/ or (remission$ or medication$ or pharmacotherapy$ or treatment outcome$).ti,ab.)				Humans; English language; randomized controlled trials; no date limits
Google Scholar	Nov-25	"exercise" AND "depression" AND ("remission" OR "medication" OR "treatment")				First 500 records sorted by relevance; no date limits; English only
Additional sources	Nov-25	Reference lists of included studies and relevant reviews (snowball searching); hand-searching of key journals (Mental Health and Physical Activity, Journal of Affective Disorders, Depression and Anxiety)				Not applicable

Table 1: Database search strategies. Complete search syntax used for each database, including controlled vocabulary (MeSH, Emtree), keywords, field tags, Boolean operators, and truncation. Searches were conducted in November 2025. Limits applied: human studies, English language, no date restrictions (except where noted). Legend: #1, #2, #3 = sequential search set numbers representing successive search steps. Truncation symbols were used to capture variant word endings (e.g., exercise retrieves exercise, exercises, and exercising): $ in Ovid and * in PubMed and Cochrane. For Ovid searches, the database searched was MEDLINE (Ovid platform). Due to Google Scholar's limitations on complex Boolean searching, a simplified search string was used; results were restricted to the first 500 records sorted by relevance. The Google Scholar search was conducted on 15 November 2025 at 10:00 AM GMT, with personalization disabled. Abbreviations: MeSH = Medical Subject Headings (PubMed); /exp = explode (Emtree terms in Embase); ti, ab = title and abstract; kw = keywords (Cochrane); kw = author keywords (OVID); All Fields = unqualified search across all indexed fields. Please click here to download this Table.

Study	D1: Randomization	D2: Deviations	D3: Missing data	D4: Outcome measurement	D5: Reported result	Overall
Nimmo, 198624	Some concerns	High risk	High risk	Some concerns	Some concerns	High risk
Doyne, 198725	Some concerns	High risk	Some concerns	Some concerns	Some concerns	High risk
McNeil, 199126	Some concerns	High risk	High risk	Some concerns	Some concerns	High risk
Veale, 199227	High risk	High risk	Some concerns	High risk	High risk	High risk
Singh, 199728	High risk	High risk	High risk	High risk	Some concerns	High risk
Mather, 200229	High risk	High risk	Some concerns	High risk	Some concerns	High risk
Nabkasorn, 200530	Low risk	Low risk	High risk	Low risk	High risk	High risk
Singh, 200531	Low risk	Some concerns	Low risk	Low risk	Some concerns	Some concerns
Sims, 200632	Some concerns	Some concerns	High risk	Some concerns	Some concerns	High risk
Brenes, 200733	Some concerns	High risk	Some concerns	Some concerns	Some concerns	High risk
Blumenthal, 200734	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Pilu, 200735	High risk	High risk	High risk	Some concerns	High risk	High risk
Vieira, 200736	High risk	High risk	High risk	Some concerns	High risk	High risk
Williams, 200837	Some concerns	Some concerns	High risk	Some concerns	Some concerns	High risk
Sims, 200938	Low risk	Some concerns	Some concerns	Low risk	Some concerns	Some concerns
Shahidi, 201139	Some concerns	Some concerns	Low risk	Low risk	Some concerns	Some concerns
Mota-Pereira, 201140	Low risk	Some concerns	Some concerns	Low risk	Low risk	Some concerns
Prakhinkit, 201341	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Legrand, 201442	Some concerns	Some concerns	Low risk	Low risk	Low risk	Some concerns
Pfaff, 201443	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Danielsson, 201444	Low risk	Some concerns	Some concerns	Low risk	Low risk	Some concerns
Oertel-Knöchel, 201445	High risk	High risk	High risk	Some concerns	High risk	High risk
Hallgren, 201546	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Carneiro, 201547	Low risk	Some concerns	Some concerns	Low risk	Low risk	Some concerns
Doose, 201548	Low risk	Some concerns	Some concerns	Low risk	Low risk	Some concerns
Schuch, 201549	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Gao, 201650	Low risk	Some concerns	Some concerns	Low risk	Some concerns	Some concerns
Schneider, 201651	Some concerns	Some concerns	High risk	Low risk	Some concerns	High risk
Lok, 201752	Low risk	Low risk	Low risk	High risk	Low risk	High risk
Cheung, 201853	Low risk	Low risk	Some concerns	Low risk	Low risk	Some concerns
Roy, 201854	Low risk	Some concerns	Some concerns	Low risk	Low risk	Some concerns
Abdelbasset, 201955	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Makizako, 202056	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
La Rocque, 202157	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Chau, 202258	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Nicholas, 202459	Some concerns	Some concerns	Low risk	Low risk	Some concerns	Some concerns
Woolf, 202460	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
James Vibin, 202461	Low risk	Some concerns	Low risk	Low risk	Low risk	Some concerns
Chang, 202562	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Wei, 202563	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk

Table 2: Risk-of-bias assessment for included studies using RoB 2. This table presents the risk‑of‑bias judgments for each of the 40 included randomized controlled trials, assessed using the Cochrane RoB 2 tool (version August 2019). Five domains are evaluated for each study: D1 (randomization process), D2 (deviations from intended interventions), D3 (missing outcome data), D4 (outcome measurement), and D5 (selection of the reported result). For each domain, the judgment is classified as “low-risk of bias”, “some concerns”, or “high risk of bias”. The overall risk‑of‑bias judgment is derived according to RoB 2 algorithms: “low-risk” if all domains are low-risk, “some concerns” if at least one domain has some concerns but no high‑risk domains, and “high risk” if any domain is rated high risk or multiple domains have some concerns. Inter‑rater agreement for overall judgments was substantial (κ = 0.79). Studies were not excluded based on risk of bias; instead, sensitivity analyses restricted to low‑risk and low‑risk‑plus‑some‑concerns studies were performed. Abbreviations: D1 = Randomization process; D2 = Deviations from intended interventions; D3 = Missing outcome data; D4 = Outcome measurement; D5 = Selection of reported result. Please click here to download this Table.

Subgroup variable	Subgroup level	No. of studies	Effect estimate (OR or MD) [95% CI]	I² (%)	p for interaction	Pooled SMD (95% CI)
Exercise mode	Aerobic	24	OR 2.54 [2.01–3.21]	44%	0.68	−0.92 (−1.28 to −0.56)
	Resistance	8	OR 2.38 [1.72–3.29]	41%		−1.04 (−1.45 to −0.63)
	Mixed	6	OR 1.92 [1.31–2.81]	52%		−0.78 (−1.18 to −0.38)
	Other (yoga/dance)	2	OR 2.15 [1.23–3.76]	0%		−0.85 (−1.32 to −0.38)
Supervision	Supervised	31	OR 2.71 [2.18–3.36]	45%	0.04	−1.12 (−1.48 to −0.76)
	Unsupervised	9	OR 1.88 [1.34–2.64]	39%		−0.65 (−1.02 to −0.28)
Control type	Passive (waitlist/usual care/no intervention)	24	OR 2.89 [2.31–3.61]	42%	0.02	−1.18 (−1.56 to −0.80)
	Active (attention/pharmacotherapy/psychotherapy)	16	OR 1.79 [1.34–2.38]	51%		−0.68 (−1.05 to −0.31)
Depression diagnosis	Formal MDD diagnosis	20	OR 2.32 [1.82–2.95]	49%	0.41	−0.98 (−1.35 to −0.61)
	Screening tool cutoff	20	OR 2.61 [1.99–3.42]	46%		−0.92 (−1.30 to −0.54)
Risk of bias (RoB 2)	Low risk	12	OR 2.08 [1.52–2.85]	38%	0.34	−0.48 (−0.82 to −0.14)
	Some concerns	13	OR 2.68 [1.94–3.70]	44%		−1.06 (−1.45 to −0.67)
	High risk	15	OR 2.54 [1.81–3.56]	51%		−1.14 (−1.52 to −0.76)
Sample size (total N)	Small (<50)	16	OR 2.58 [1.86–3.58]	48%	0.28	−1.08 (−1.48 to −0.68)
	Medium (50–99)	16	OR 2.61 [1.99–3.42]	46%		−0.96 (−1.34 to −0.58)
	Large (≥100)	8	OR 1.96 [1.45–2.65]	35%		−0.72 (−1.10 to −0.34)
Age group	Adults (18–59 years)	20	OR 2.44 [1.94–3.07]	47%	0.92	−0.94 (−1.32 to −0.56)
	Older adults (≥60 years)	20	OR 2.48 [1.88–3.27]	49%		−0.98 (−1.36 to −0.60)
Exercise duration	Short (≤8 weeks)	16	OR 2.61 [2.01–3.39]	43%	0.58	−1.02 (−1.40 to −0.64)
	Medium (9–12 weeks)	18	OR 2.38 [1.84–3.08]	49%		−0.94 (−1.32 to −0.56)
	Long (≥13 weeks)	6	OR 2.28 [1.51–3.44]	52%		−0.82 (−1.22 to −0.42)
Publication year	Pre-2010	14	OR 2.32 [1.76–3.06]	51%	0.67	−0.88 (−1.26 to −0.50)
	2010–2019	17	OR 2.51 [1.93–3.26]	46%		−0.98 (−1.36 to −0.60)
	2020–2025	9	OR 2.54 [1.88–3.43]	44%		−1.02 (−1.40 to −0.64)

Table 3: Subgroup analysis results. This table displays the results of prespecified subgroup analyses examining potential moderators of exercise efficacy on depression remission (odds ratio). Subgroup variables include exercise characteristics (mode, supervision, duration), population characteristics (depression diagnosis type, age group, baseline severity), and study design features (control group type, risk of bias, sample size, publication year). For each subgroup level, the table reports the number of studies, the pooled odds ratio with 95% confidence interval, the I² statistic for heterogeneity, and the p‑value for interaction between subgroups. A p‑value for interaction of less than 0.10 was considered statistically significant, acknowledging the low power of interaction tests in meta‑analyses. Statistically significant subgroup differences (p < 0.10) are bolded in the table. Control group type was categorized as passive (waitlist, usual care, no intervention) or active (attention control, pharmacotherapy, psychotherapy). Risk of bias was assessed using the Cochrane RoB 2 tool. All subgroup analyses used random‑effects models (DerSimonian and Laird method). Bolded p for interaction values indicates statistically significant subgroup differences (p < 0.10). Please click here to download this Table.

Outcome	No. of participants (Studies)	Effect estimate (95% CI)	Certainty assessment			GRADE certainty
Depression remission	2667 (40 RCTs)	OR 2.40 (1.97–2.93)	Risk of bias: Serious (−1) – 37.5% of studies high risk			Moderate ◯
			Inconsistency: Not serious – I² = 48%, prediction interval 1.28–4.73 (does not cross 1.0)
			Indirectness: Not serious – direct comparison
			Imprecision: Not serious – OIS met, CI excludes no effect
			Publication bias: Not detected (Egger p = 0.87)
Depression severity (SMD)	2667 (40 RCTs)	SMD −0.96 (−1.27−0.65)	Risk of bias: Serious (−1) – 37.5% of studies high risk			Low ◯◯
			Inconsistency: Serious (−1) – I² = 87%, prediction interval −1.42 to 0.20 (crosses zero)
			Indirectness: Not serious – direct comparison
			Imprecision: Not serious – OIS met
			Publication bias: Not detected (Egger p = 0.68)

Table 4: Summary of findings (GRADE) – Exercise compared to control for depression symptoms. This table presents the Grading of Recommendations Assessment, Development and Evaluation (GRADE) certainty of evidence for the two primary outcomes: depression remission (dichotomous) and depression severity (continuous, reported as standardized mean difference). For each outcome, the table shows the number of participants and studies, the pooled effect estimate with 95% confidence interval, and a structured certainty assessment across five domains: risk of bias (based on RoB 2 assessments), inconsistency (based on I² statistic and prediction intervals), indirectness (based on population, intervention, comparator, and outcome differences), imprecision (based on optimal information size and confidence interval crossing of clinically important thresholds), and publication bias (based on funnel plot asymmetry and Egger's test). Certainty is graded as high, moderate, low, or very low. For remission, certainty was downgraded by one level for serious risk of bias, resulting in moderate certainty. For depression severity scores, certainty was downgraded by one level for serious risk of bias and an additional level for very serious inconsistency (I² = 87% and prediction interval crossing zero), resulting in low certainty. Explanation of certainty ratings: Moderate certainty (remission): authors are moderately confident that the true effect is likely close to the estimated effect, although further research may change this estimate. Low certainty (depression scores): authors have limited confidence in the estimated effect; the true effect may differ substantially from the estimate, as reflected by the wide prediction interval crossing the line of no effect and the very high statistical heterogeneity (inconsistency). Abbreviations: OR = odds ratio; SMD = standardized mean difference; CI = confidence interval; OIS = optimal information size; GRADE = Grading of Recommendations Assessment, Development and Evaluation. Please click here to download this Table.

Supplementary Table 1: Characteristics of the 40 included studies in the meta-analysis. Studies are ordered chronologically by publication year. All values represent the number of participants (n) unless otherwise specified. Total sample sizes include all randomized participants (intention-to-treat populations where reported). For studies with multiple exercise arms, exercise group counts represent the sum of participants across exercise arms, and control group counts represent the original control arm (not divided) to avoid double-counting (see Methods for handling of multi-arm trials). Legend: Country names are reported as presented in the original studies. Exercise (n) = number of participants randomized to the exercise intervention group(s); for studies with multiple exercise arms, n represents the combined sample size across all exercise arms. Control (n) = number of participants randomized to the control (non-exercising) group; for studies with multiple control arms, only the non-exercising control group was included, using the following prioritization hierarchy: waitlist > usual care > attention control > pharmacotherapy > psychotherapy. Sample sizes reflect the number of participants randomized at baseline and do not account for attrition during follow-up. For studies published before 2001 (pre-CONSORT era; n = 5: Nimmo 1986, Doyne 1987, McNeil 1991, Veale 1992, and Singh 1997), sample sizes are reported as stated in the original publications. No studies required imputation of missing sample size data. Control type classification: Passive = waitlist, usual care, or no intervention; Active = attention control, pharmacotherapy, or psychotherapy. Studies with multiple control arms were handled according to the hierarchical selection approach described in the Methods, with passive controls prioritized over active controls. Abbreviations: N = total sample size (exercise + control participants); UK = United Kingdom; USA = United States of America; N/A = not applicable.Please click here to download this file.

Supplementary File 1: NEW PRISMA checklist.Please click here to download this file.

Discussion

This meta‑analysis of 40 randomized controlled trials (2,667 participants with depression)^{24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,
58,59,60,61,62,63}, found that exercise significantly increased remission rates (OR = 2.40; 95% CI, 1.97–2.93; I² = 49%) and reduced depression severity scores (SMD = −0.96; 95% CI, −1.27 to −0.65; I² = 87%) compared to non‑exercising controls. The number needed to treat for one additional remission was 2.1, and the pooled SMD translated into clinically meaningful reductions (≈6.5 Beck Depression Inventory points, ≈4.7 Hamilton Depression Rating Scale points). These findings provide preliminary support for exercise as an effective complementary intervention for depression, particularly for achieving remission. However, the very high heterogeneity for continuous outcomes (I² = 87%) and the fact that only 12 of 40 studies (30%) were rated as low-risk of bias warrant cautious interpretation. Substantial heterogeneity for depression scores arises from multiple sources: variations in exercise protocols, intervention duration (3–16 weeks), supervision status, control group types (waitlist, usual care, pharmacotherapy, psychotherapy), baseline depression severity, and outcome scales^15,16. The included studies employed diverse modalities—aerobic, resistance, mixed, yoga, tai chi, and dance—which may differ in antidepressant mechanisms, acceptability, and adherence¹⁶.

Subgroup analyses showed no clear superiority of any single modality, but supervised exercise produced larger effects than unsupervised (p = 0.04), and passive controls (waitlist/usual care) yielded larger effects than active comparators (p = 0.02). These findings indicate that both the nature of the intervention and the choice of comparator influence observed effect sizes. Light‑intensity and low‑burden exercise options warrant further consideration, as many patients with depression have low baseline fitness, fatigue, and low motivation^64,65. Future studies should test whether such interventions produce clinically meaningful effects in populations unable or unwilling to engage in moderate‑to‑vigorous intensity programs. These results align with Schuch et al. (2016; SMD = −0.62)^10,11,12 but extend the evidence base by including 23 additional trials published since 2019. Unlike Krogh et al. (2017)¹², who found no effect when restricting to low‑risk‑of‑bias trials, the present sensitivity analysis, limited to low-risk studies, still showed a significant but attenuated effect (SMD = −0.48). This discrepancy may reflect the use of the updated RoB 2 tool and the inclusion of more recent high‑quality trials. The number needed to treat (NNT = 2.1) compares favorably with published NNTs for psychotherapy (2.5)⁶⁶ and antidepressant medication (4.3)⁶⁷, although these are indirect comparisons. NNT for medication is derived from placebo‑controlled trials with strict blinding, whereas NNT for exercise comes from open‑label trials; the apparent superiority of exercise may reflect expectancy effects or heterogeneity in control conditions rather than true biological superiority. Thus, the NNT comparison is intended for hypothesis generation, not to claim that exercise is better than medication. Only six studies reported outcomes at ≥6 months, and these showed attenuated effects (SMD = −0.31 vs. −0.96 post‑intervention), indicating that benefits may diminish without ongoing intervention. Clinicians should consider exercise as an adjunct to established treatments, particularly for motivated⁶⁸, physically able patients with access to supervised programs⁶⁹.

Several important limitations are present. First, eligibility criteria were not fully pre‑specified, and a protocol (e.g., PROSPERO) was not registered, increasing the risk of reporting bias. Second, the very high heterogeneity for depression severity (I² = 87%) persisted despite using SMD; the 95% prediction interval crossed zero, meaning exercise may not be beneficial in some future settings or populations. Third, most studies had short follow‑up (≤16 weeks), small sample sizes (only eight studies with ≥100 participants), and were conducted in high‑income countries, limiting generalizability to low‑resource settings. Fourth, placebo effects cannot be excluded due to inherent difficulties in blinding participants to exercise versus control. Fifth, only 15.9% of studies provided adjusted effect estimates (ANCOVA); more than half contributed only post‑intervention scores without baseline adjustment. Sixth, for studies reporting change scores, a correlation coefficient of r = 0.5 was assumed when calculating standard deviations, which may not reflect true within‑study correlations. Finally, adherence barriers related to depression symptoms—low motivation, fatigue, anhedonia—are rarely captured in efficacy trials but are highly relevant for real‑world translation⁷⁰.

A notable inconsistency in the inclusion criteria should be acknowledged. Although the Innovation section stated that studies with active psychological interventions or stretching/relaxation controls were excluded, the eligibility criteria in the Methods accepted pharmacotherapy and psychotherapy as comparators, and Supplementary Table 1 includes several such studies. This discrepancy arose from an evolving definition of “non‑exercising control” during the review process. Sensitivity analyses stratifying by control type (Table 3) showed significantly larger effects for passive controls (OR = 2.89) than for active controls (OR = 1.79; p = 0.02), indicating that inclusion of active comparators attenuates the overall estimate. Readers should interpret the pooled effect sizes as reflecting a mix of passive and active comparators. Future research should stratify analyses by control condition type or restrict comparisons to non‑active controls only. Additionally, digital and remote exercise interventions (online programs, telehealth coaching, wearable monitors) represent an emerging and potentially scalable approach to managing depression^71,72, but none of the trials in this meta‑analysis evaluated these formats. Future RCTs should directly compare digitally delivered exercise to in‑person exercise and to non‑exercising controls^71,72.

Exercise was associated with significantly higher remission rates and lower depression scores in patients with depression, but the evidence is limited by high heterogeneity, short follow‑up, and methodological concerns. The GRADE certainty was moderate for remission but low for depression severity scores. Therefore, exercise should currently be recommended as an effective complementary intervention rather than a standalone first‑line treatment. High‑quality, large‑scale randomized controlled trials with longer follow-up, standardized outcome measures, diverse populations, and prespecified subgroup analyses by exercise modality are urgently needed. Future trials should also examine which patients benefit most from which exercise regimen, test light‑intensity and remote delivery formats, and report adverse events and adherence barriers. In the meantime, clinicians should consider patient preferences, physical capabilities, and access to resources when prescribing exercise as part of a comprehensive depression treatment plan^73,74.

In conclusion, exercise was associated with significantly higher remission rates (low heterogeneity) and a significantly lower depression score (very high heterogeneity) in patients with depression. Given the substantial heterogeneity for continuous depression outcomes and the methodological limitations of many included studies, these findings provide preliminary rather than definitive support for exercise in depression management. High-quality, large-scale randomized controlled trials with standardized outcome measures are needed before exercise can be recommended as a stand-alone treatment. Clinicians should consider exercise as a potential complementary intervention while awaiting more robust evidence. An additional limitation concerns the pooling of depression scores. Included studies used at least six different depression rating scales (HAM-D, BDI, CES-D, PHQ-9, GDS, and others), each with different ranges and clinical interpretations. Future meta-analyses should consider pooling only studies that use the same scale or performing sensitivity analyses stratified by scale type. The very high heterogeneity (I² = 87%) underscores the impact of measurement diversity on pooled estimates. Adherence barriers related to depression symptoms deserve specific attention. Depression-related symptoms such as low motivation, fatigue, anhedonia, and reduced perceived capacity for effort may substantially affect exercise initiation and adherence in real-world settings. These factors are rarely captured in efficacy trials but are highly relevant for translating findings into clinical and community practice. Designing feasible, low-burden exercise programs that account for these motivational and effort-perception barriers is essential. However, none of the trials in this meta‑analysis evaluated these formats, and the current evidence base for remote delivery is limited by small sample sizes, short follow‑up, and lack of active comparators. Home-based, wearable-supported, or remotely coached exercise models may improve accessibility and scalability, particularly for patients who cannot access supervised facility-based programs. Future RCTs should directly compare digitally delivered exercise to in‑person exercise and to non‑exercising controls, while addressing barriers such as the digital divide and adherence. Until then, remote exercise should be viewed as a complementary option, not a replacement for supervised programs.

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
Assumed correlation coefficient for change-score SD	Imputation of Missing Data	Cochrane Handbook default	r = 0.5 (sensitivity analysis performed)
ClinicalTrials.gov	Clinical Trial Registries	U.S. National Library of Medicine	Database as of November 10, 2025 (no NCT-specific filter)
Cochrane Central Register of Controlled Trials (CENTRAL)	Databases	Cochrane Library	Issue 11 of 12, November 2025
Cochrane Handbook formulas	Formulas & Calculations	Cochrane Collaboration	Handbook version 6.4 (updated September 2024)
Egger’s linear regression test	Funnel Plot Asymmetry	RevMan 5.3 / custom macro	N/A
Embase (OVID platform)	Databases	Elsevier / OVID Technologies	Embase Classic+Embase 1947 to 2025 Week 47
EndNote	Reference Management	Clarivate Analytics (London, UK)	Version 20 (build 20.1.0.16478)
Google Scholar	Databases	Google LLC	Search conducted November 15–16, 2025 (first 500 records by relevance)
GRADE (Grading of Recommendations Assessment, Development and Evaluation)	Certainty of Evidence	GRADE Working Group	GRADEpro GDT (online version, accessed November 2025)
MEDLINE (OVID platform)	Databases	OVID Technologies	Ovid MEDLINE® 1946 to November 14, 2025
NNT from SMD (Furukawa & Leucht method)	Effect Size Conversion	Based on area under normal curve	N/A
Number needed to treat (NNT) from OR	Effect Size Conversion	Formula: NNT = 1 / [CER × (1 – OR-¹)]	N/A
PubMed	Databases	U.S. National Library of Medicine	NLM ID: 101775772 (database version 2025)
Review Manager (RevMan)	Statistical & Meta-Analysis Software	Cochrane Collaboration	Version 5.3 (Copenhagen: The Nordic Cochrane Centre)
RoB 2 tool	Risk of Bias Assessment	Cochrane Collaboration	Version: August 2019 (latest update)
Standardized mean difference (Hedges’ g)	Effect Size Conversion	Custom calculations in RevMan 5.3	N/A
WHO International Clinical Trials Registry Platform (ICTRP)	Databases	World Health Organization	Search portal version 1.6 (accessed November 2025)